Key result
Two cIPV booster vaccinations in adults previously vaccinated with OPV maintained high antibody levels against poliovirus types 1 and 2 exceeding detection limits at 10 years.
Why the study?
Childhood two-dose oral polio vaccination in Japan is considered suboptimal by global standards, and the long-term persistence of anti-poliovirus antibodies after booster doses with conventional inactivated poliovirus vaccine in Japanese adults remains unclear.
Does two-dose booster immunization with conventional inactivated poliovirus vaccine (cIPV) provide long-term persistence of anti-poliovirus antibody titers in Japanese adults previously vaccinated with OPV?
Observational (n=10)
Does two-dose booster immunization with conventional inactivated poliovirus vaccine (cIPV) provide long-term persistence of anti-poliovirus antibody titers in Japanese adults previously vaccinated with OPV?
Two cIPV booster vaccinations provide long-lasting protective immunity against poliovirus types 1 and 2 for at least 10 years in adults previously vaccinated with OPV.
Answers are grounded in this paper and cite their sources.
Supports durable type 1/2 seropositivity after cIPV boosters in OPV-primed adults; leaves open type 3 waning and booster needs in larger prospective studies.
Background/Objectives: Most Japanese adults received two doses of the oral polio vaccine (OPV) during childhood as part of the national immunization program. However, these two doses are considered suboptimal by global standards. The long-term persistence of anti-poliovirus antibodies after booster doses with the conventional inactivated poliovirus vaccine (cIPV) in Japanese adults remains unclear. This study was performed to evaluate long-term immunogenicity over a 10-year period following two cIPV booster vaccinations. Methods: Ten out of sixty-one adult participants in a short-term study were enrolled to assess the long-term immunogenicity of the booster vaccination. They underwent blood sampling at 3, 5, and 10 years after cIPV vaccination. Results: The results indicate that, even 10 years after the booster vaccination, antibodies against poliovirus types 1 and 2 remained at high levels, exceeding the detection limits of neutralization tests. However, some participants showed decreased antibody levels against poliovirus type 3. Conclusions: This study showed that cIPV boosters provided long-lasting protective immunity against poliovirus types 1 and 2 in adults who were vaccinated with OPV. These findings are valuable in assessing the need for IPV booster vaccinations in adults.
No takes yet. Share an insight, caveat, or question.
Fukushima et al. (2025) conducted an observational in Poliovirus immunity (n=10). Two cIPV booster vaccinations was evaluated on Long-term immunogenicity (anti-poliovirus antibody titers). Two cIPV booster vaccinations in adults previously vaccinated with OPV maintained high antibody levels against poliovirus types 1 and 2 exceeding detection limits at 10 years.
Synapse has enriched 10 related papers. Consider them for comparative context: